Peer-Reviewed Publications

      Systems toxicology approach to unravel early indicators of squamous cell carcinoma rate in rat nasal epithelium induced by formaldehyde exposure

      Martin, F.; Talikka, M.; Hoeng, J.; Peitsch, M. C.
      Published
      Jun 22, 2019
      DOI
      10.1007/978-3-030-23873-5_3
      Link to publication
      Topic
      Summary

      Causal biological network models consisting of multiple biological pathways involved in a given biological process can serve to contextualize gene expression changes and unravel key mechanisms responsible for those changes. The transcriptomic data from the respiratory nasal epithelium (RNE) of rats exposed to formaldehyde have been investigated using such causal biological network models. The resulting association between the biological impact assessed by network perturbation and the squamous cell carcinoma rate in the RNE after two years has been further investigated to gain mechanistic insights. A detailed node-level investigation revealed that while similar network models were impacted across exposure doses, the directionality of the effect was opposite for the lowest doses compared to high doses. In particular, NF-κB was inferred to be upregulated in response to the two higher doses and downregulated in response to the lower doses in the context of the epithelial innate immune activation network model. This highlighted a dose threshold indicative of a long-term biphasic effect of formaldehyde exposure leading to carcinogenicity. The presented approach could be used to establish the mechanism of action or grouping of compounds based on impacted regions in the network models.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.